18 Hrs
Source:
الصحة والعلوم الشرق الأوسط
Saudi Arabia approves multiple myeloma treatment
The Saudi Food and Drug Authority (SFDA) has approved the registration of the medication "Iberdomide" for the treatment of adult patients with relapsed or refractory multiple myeloma, making it the first regulatory body in the world to do so. The medication is used in combination with Daratumumab and Dexamethasone and aims to improve treatment outcomes by stimulating the breakdown of proteins that assist in the survival and growth of tumor cells, as well as enhancing the immune system's ability to attack them. Results from a Phase III clinical trial demonstrated a statistically significant improvement compared to standard therapy. Side effects observed include decreases in blood cells, dizziness, nausea, and rash, and it must be used under direct medical supervision. This decision reflects the Authority’s commitment to supporting innovation and providing modern therapeutic options to enhance the quality of healthcare in the Kingdom, in line with the objectives of the Healthcare Transformation Program and Saudi Vision 2030.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)